Global Health Ingredients Market to Reach $118.5 Billion by 2027
Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 6. - Influencer Pool: 1974. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.
New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Generic Drugs Industry" - https://www.reportlinker.com/p06041415/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.
Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.
Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.
Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.
Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.
Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.
Abstract:
- Global Generic Drugs Market to Reach $535.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$286 Billion in the year 2020, is projected to reach a revised size of US$535.5 Billion by 2027, growing at aCAGR of 9.4% over the period 2020-2027. Pure Generic Drugs, one of the segments analyzed in the report, is projected to record 9.1% CAGR and reach US$353.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Branded Generic Drugs segment is readjusted to a revised 9.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $77.3 Billion, While China is Forecast to Grow at 12.5% CAGR
- The Generic Drugs market in the U.S. is estimated at US$77.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$112.2 Billion by the year 2027 trailing a CAGR of 12.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.
- Select Competitors (Total 42 Featured) -
Fresenius Kabi AG
Mylan Pharmaceuticals, Inc.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Generic Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 2: World Historic Review for Generic Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 3: World 15-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Pure Generic Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Pure Generic Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Pure Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Branded Generic
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Branded Generic Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Branded Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Central Nervous
System (CNS) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Central Nervous System
(CNS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Central Nervous System
(CNS) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 13: World Current & Future Analysis for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Dermatology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 17: World Historic Review for Dermatology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 18: World 15-Year Perspective for Dermatology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 21: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Respiratory by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 23: World Historic Review for Respiratory by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Respiratory by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 25: World Current & Future Analysis for Other Therapeutic
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 26: World Historic Review for Other Therapeutic
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Other Therapeutic
Applications by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 28: USA Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for Generic Drugs by Type - Pure
Generic Drugs and Branded Generic Drugs Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 30: USA 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 31: USA Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: USA Historic Review for Generic Drugs by Therapeutic
Application - Central Nervous System (CNS), Cardiovascular,
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 33: USA 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
CANADA
Table 34: Canada Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 35: Canada Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 36: Canada 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 37: Canada Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Canada Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 39: Canada 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
JAPAN
Table 40: Japan Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 41: Japan Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 42: Japan 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 43: Japan Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: Japan Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 45: Japan 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
CHINA
Table 46: China Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 47: China Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 48: China 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 49: China Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 50: China Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 51: China 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
EUROPE
Table 52: Europe Current & Future Analysis for Generic Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Generic Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 56: Europe Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 57: Europe 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 58: Europe Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: Europe Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 60: Europe 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
FRANCE
Table 61: France Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 62: France Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 63: France 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 64: France Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 65: France Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 66: France 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
GERMANY
Table 67: Germany Current & Future Analysis for Generic Drugs
by Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 68: Germany Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 69: Germany 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 70: Germany Current & Future Analysis for Generic Drugs
by Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Germany Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 72: Germany 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
ITALY
Table 73: Italy Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 74: Italy Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 75: Italy 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 76: Italy Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: Italy Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 78: Italy 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 79: UK Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 80: UK Historic Review for Generic Drugs by Type - Pure
Generic Drugs and Branded Generic Drugs Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 81: UK 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 82: UK Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: UK Historic Review for Generic Drugs by Therapeutic
Application - Central Nervous System (CNS), Cardiovascular,
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 84: UK 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
SPAIN
Table 85: Spain Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 86: Spain Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 87: Spain 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs and
Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 88: Spain Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Spain Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 90: Spain 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
RUSSIA
Table 91: Russia Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 92: Russia Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 93: Russia 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 94: Russia Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 95: Russia Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 96: Russia 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
REST OF EUROPE
Table 97: Rest of Europe Current & Future Analysis for Generic
Drugs by Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 98: Rest of Europe Historic Review for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 99: Rest of Europe 15-Year Perspective for Generic Drugs
by Type - Percentage Breakdown of Value Sales for Pure Generic
Drugs and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 100: Rest of Europe Current & Future Analysis for Generic
Drugs by Therapeutic Application - Central Nervous System
(CNS), Cardiovascular, Dermatology, Oncology, Respiratory and
Other Therapeutic Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 101: Rest of Europe Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 102: Rest of Europe 15-Year Perspective for Generic Drugs
by Therapeutic Application - Percentage Breakdown of Value
Sales for Central Nervous System (CNS), Cardiovascular,
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 103: Asia-Pacific Current & Future Analysis for Generic
Drugs by Geographic Region - Australia, India, South Korea and
Rest of Asia-Pacific Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 104: Asia-Pacific Historic Review for Generic Drugs by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 105: Asia-Pacific 15-Year Perspective for Generic Drugs
by Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2012, 2020 & 2027
Table 106: Asia-Pacific Current & Future Analysis for Generic
Drugs by Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 107: Asia-Pacific Historic Review for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 108: Asia-Pacific 15-Year Perspective for Generic Drugs
by Type - Percentage Breakdown of Value Sales for Pure Generic
Drugs and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 109: Asia-Pacific Current & Future Analysis for Generic
Drugs by Therapeutic Application - Central Nervous System
(CNS), Cardiovascular, Dermatology, Oncology, Respiratory and
Other Therapeutic Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 110: Asia-Pacific Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 111: Asia-Pacific 15-Year Perspective for Generic Drugs
by Therapeutic Application - Percentage Breakdown of Value
Sales for Central Nervous System (CNS), Cardiovascular,
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications for the Years 2012, 2020 & 2027
AUSTRALIA
Table 112: Australia Current & Future Analysis for Generic
Drugs by Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 113: Australia Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 114: Australia 15-Year Perspective for Generic Drugs by
Type - Percentage Breakdown of Value Sales for Pure Generic
Drugs and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 115: Australia Current & Future Analysis for Generic
Drugs by Therapeutic Application - Central Nervous System
(CNS), Cardiovascular, Dermatology, Oncology, Respiratory and
Other Therapeutic Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 116: Australia Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 117: Australia 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
INDIA
Table 118: India Current & Future Analysis for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 119: India Historic Review for Generic Drugs by Type -
Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 120: India 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Pure Generic Drugs
and Branded Generic Drugs for the Years 2012, 2020 & 2027
Table 121: India Current & Future Analysis for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 122: India Historic Review for Generic Drugs by
Therapeutic Application - Central Nervous System (CNS),
Cardiovascular, Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 123: India 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Central Nervous System (CNS), Cardiovascular, Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027
SOUTH KOREA
Table 124: South Korea Current & Future Analysis for Generic
Drugs by Type - Pure Generic Drugs and Branded Generic Drugs -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 125: South Korea Historic Review for Generic Drugs by
Type - Pure Generic Drugs and Branded Generic Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 126: South Korea 15-Year Perspective for Generic Drugs by
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001